Patient demographics and baseline characteristics
| Characteristic | N=32 |
| Sex | |
| Male | 27 (84) |
| Female | 5 (16) |
| Age, years | |
| Median (IQR) | 60 (53–65) |
| <65 | 22 (69) |
| ≥65 | 10 (31) |
| Primary tumor site | |
| Oral cavity | 11 (34) |
| Oropharynx | 7 (22) |
| Hypopharynx | 4 (13) |
| Larynx | 4 (13) |
| Nasal cavity and sinuses | 2 (6) |
| Nasopharynx | 1 (3) |
| Other* | 3 (9) |
| Number of prior anticancer therapies | |
| 1 | 8 (25) |
| 2 | 11 (34) |
| ≥3 | 13 (41) |
| Prior anticancer therapy setting | |
| For locally advanced disease only | 4 (13) |
| ≥1 prior therapy for recurrent/metastatic disease | 28 (88) |
| ECOG performance status | |
| 0 | 7 (22) |
| 1 | 25 (78) |
| PD-L1 expression | |
| <1% tumor cells | 6 (19) |
| ≥1% tumor cells | 25 (78) |
| Not evaluable | 1 (3) |
| HPV status | |
| Positive | 9 (28) |
| Negative | 22 (69) |
| Not evaluable | 1 (3) |
| Prior cetuximab | |
| Yes | 24 (75) |
| No | 8 (25) |
Data are number (%) unless stated otherwise.
*Tonsil, pharynx and larynx and tongue (n=1 each (3%)).
ECOG, Eastern Cooperative Oncology Group; HPV, human papillomavirus; PD-L1, programmed death-ligand 1.